Press – Maiwald

Press Coverage

13 Jul 2022 - Press Coverage

Royalty Pharma agrees to acquire Royalty Interest in Trelegy Ellipta from Theravance and Innoviva for $1.31 Billion and potential Milestones of $300 Million

• Further diversifies Royalty Pharma’s portfolio with market-leading respiratory therapy• Expected to significantly add to long-term Adjusted Cash Receipts growth (non-GAAP) NEW YORK, NY,...

1 Jul 2022 - Press Coverage

Proxygen announces strategic collaboration with
Merck to develop molecular glue degraders

Proxygen, a leader in the discovery and development of molecular glue degraders, announced today that the company has entered into a strategic multi-year research collaboration and license agreement with Merck. Proxygen is eligible to receive up to €495 million ($554 milli...

30 Jun 2022 - Press Coverage

Royalty Pharma acquires Royalty interest in Gavreto from Blueprint medicines for up to $340 Million

Attractive, precision oncology therapy with long patent duration added to portfolioBlueprint Medicines to receive $175 million upfront and $165 million in potential milestone payments

All press coverage

Maiwald press releases

21 Mar 2022 - Press Release

Maiwald offers part of its office space to Munich volunteer organisation as a coordination hub for Ukrainian refugees

The patent attorneys’ firm of Maiwald has put part of its Munich office space at the disposal of the organisation “Münchner Freiwillige – Wir helfen e.V.” to use as a contact point for refugees fleeing Ukraine. From rooms in Elisenhof, located very close to...

26 Apr 2021 - Press Release

Video Conference Without Consent of the Parties – Amicus Curiae Brief Filed in Connection With Case G 1/21 Before the Enlarged Board of Appeal of the EPO

Maiwald, together with other leading patent law firms, considers video conferencing without the consent of the parties to be inadmissible and has filed an amicus curiae brief in connection with the proceedings G 1/21 before the Enlarged Board of Appeal of the Europea...

8 Feb 2021 - Press Release

Maiwald establishes practice for patent litigation in the field of standard-essential HEVC patents and video codec technologies against non-practicing entities

Maiwald is setting up a patent litigation team with partner Dr Simon Lud and two associates. Maiwald is mandated by Unified Patents, LLC, located in the USA.

All press releases

Maiwald in the press

Press Coverage

Royalty Pharma agrees to acquire Royalty Interest in Trelegy Ellipta from Theravance and Innoviva for $1.31 Billion and potential Milestones of $300 Million

Proxygen announces strategic collaboration with
Merck to develop molecular glue degraders

Royalty Pharma acquires Royalty interest in Gavreto from Blueprint medicines for up to $340 Million

Maiwald press releases

Maiwald offers part of its office space to Munich volunteer organisation as a coordination hub for Ukrainian refugees

Video Conference Without Consent of the Parties – Amicus Curiae Brief Filed in Connection With Case G 1/21 Before the Enlarged Board of Appeal of the EPO

Maiwald establishes practice for patent litigation in the field of standard-essential HEVC patents and video codec technologies against non-practicing entities

Press Contact

Dr Eva Dörner

Maiwald in the press

Press Coverage

Royalty Pharma agrees to acquire Royalty Interest in Trelegy Ellipta from Theravance and Innoviva for $1.31 Billion and potential Milestones of $300 Million

Proxygen announces strategic collaboration withMerck to develop molecular glue degraders

Royalty Pharma acquires Royalty interest in Gavreto from Blueprint medicines for up to $340 Million

Maiwald press releases

Maiwald offers part of its office space to Munich volunteer organisation as a coordination hub for Ukrainian refugees

Video Conference Without Consent of the Parties – Amicus Curiae Brief Filed in Connection With Case G 1/21 Before the Enlarged Board of Appeal of the EPO

Maiwald establishes practice for patent litigation in the field of standard-essential HEVC patents and video codec technologies against non-practicing entities

Press Contact

Dr Eva Dörner

Proxygen announces strategic collaboration with
Merck to develop molecular glue degraders